Search

Author/Creator Rybka, Witold B.

1. A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. Issue 2 (23rd November 2020)

Authors:
Zheng, Hong; Mineishi, Shin; Claxton, David; Zhu, Junjia; Zhao, Chenchen; Jia, Bei; Ehmann, W. Christopher; Rybka, Witold B.; Naik, Seema; Songdej, Natthapol; Drabick, Joseph J.; Hohl, Raymond J.
Journal:
American journal of hematology
Issue:
Volume 96:Issue 2(2021)
Page Start:
E46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Issue 1 (15th November 2018)

Authors:
Litzow, Mark R.; Wang, Xin V.; Carroll, Martin P.; Karp, Judith E.; Ketterling, Rhett P.; Zhang, Yanming; Kaufmann, Scott H.; Lazarus, Hillard M.; Luger, Selina M.; Paietta, Elisabeth M.; Pratz, Keith W.; Tun, Han Win; Altman, Jessica K.; Broun, Edward R.; Rybka, Witold B.; Rowe, Jacob M.; Tallma...
Journal:
American journal of hematology
Issue:
Volume 94:Issue 1(2019:Jan.)
Page Start:
111
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. (1st October 2019)

Authors:
Zhao, Chenchen; Jia, Bei; Wang, Ming; Schell, Todd D.; Claxton, David F.; Ehmann, W Christopher; Rybka, Witold B.; Mineishi, Shin; Naik, Seema; Songdej, Natthapol; Sivik, Jeff M.; Hohl, Raymond J.; Zeng, Hui; Zheng, Hong
Journal:
British journal of haematology
Issue:
Volume 188:Number 5(2020)
Page Start:
674
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. (December 2021)

Authors:
Luger, Selina M.; Wang, Victoria X.; Rowe, Jacob M.; Litzow, Mark R.; Paietta, Elisabeth; Ketterling, Rhett P.; Lazarus, Hillard; Rybka, Witold B.; Craig, Michael D.; Karp, Judith; Cooper, Brenda W.; Makary, Adel Z.; Kaminer, Lynne S.; Appelbaum, Frederick R.; Larson, Richard A.; Tallman, Martin S.
Journal:
Leukemia research
Issue:
Volume 111(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. (2nd September 2018)

Authors:
Wang, Liru; Jia, Bei; Claxton, David F.; Ehmann, W Christopher; Rybka, Witold B.; Mineishi, Shin; Naik, Seema; Khawaja, Muhammad R.; Sivik, Jeff; Han, Junyan; Hohl, Raymond J.; Zheng, Hong
Journal:
Oncoimmunology
Issue:
Volume 7:Number 9(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗